63.1% of NNP. ABBREVIATION & OUR PROJECTSFINANCIAL PERFORMANCE FINANCIAL POSITION PROGRESS OF PROJECTS UNDER CONSTRUCTION EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’2017 6M’2018 % change Q1’2018 Q2’2018
EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 9M’18 9M’19 change Q3’18 Q2’19 Q3’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 26,652 32,874 23.3% 9,691 10,866 11,751 21.3
EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’18 6M’19 change Q2’18 Q1’19 Q2’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 16,961 21,123 24.5% 8,805 10,257 10,866 23.4
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1
–2021 Balance by Quarter Change Q2–21 Q1–21 Q2–20 Q2–21 VS Q1–21 Q2–21 VS Q2–20 (Million Baht: MB) (MB) % (MB) % Total revenue 2,081.2 1,824.2 1,187.6 257.0 14.1 893.6 75.2 Total operating expenses
increased or decreased according to the change of business circumstance and relevant factors in the near future while the fixing of the base price with certain discount will be used as a minimum price
review the information disclosed or disseminated regularly or every time there is a change or an update so that the information is current. Clause 17 Securities clearing houses and central securities
shareholders’ meeting of the Company shall have approved the entering into the Transaction; and (2) No change has occurred, which causes a material adverse effect on assets, liabilities, business opportunity
relevant agreements are as follows: (1) The shareholders’ meeting of the Company shall have approved the entering into the Transaction; and (2) No change has occurred, which causes a material adverse effect